---
title: How I Treat AML relapse after allogeneic HCT
date: '2024-12-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39719042/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241225170554&v=2.18.0.post9+e462414
source: Blood
description: Allogeneic hematopoietic stem-cell transplantation (HCT) is one of the
  principal curative approaches in the treatment of acute myeloid leukemia (AML);
  however, relapse post-transplantation remains a catastrophic event with poor prognosis.
  The incidence of relapse has remained unchanged over the last three decades despite
  an evolving understanding of the immunobiology of the graft-versus leukemia effect
  and the immune escape mechanisms that lead to post-HCT relapse. The approach ...
disable_comments: true
---
Allogeneic hematopoietic stem-cell transplantation (HCT) is one of the principal curative approaches in the treatment of acute myeloid leukemia (AML); however, relapse post-transplantation remains a catastrophic event with poor prognosis. The incidence of relapse has remained unchanged over the last three decades despite an evolving understanding of the immunobiology of the graft-versus leukemia effect and the immune escape mechanisms that lead to post-HCT relapse. The approach ...